Skip to content
HowShorted

Perspective Therapeutics, Inc. short interest in 2022

In 2022, Perspective Therapeutics, Inc.'s disclosed short interest ran from 0.61% of shares outstanding on 14 Jan 2022 to 0.32% on 30 Dec 2022, a change of -0.29 percentage points. The year's high was 0.73% on 14 Oct 2022 and its low 0.32% on 30 Dec 2022, averaging 0.49% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 3.93 days on 15 Sep 2022. Full history: Perspective Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Perspective Therapeutics, Inc. in 2022

2022 in figures

Start of year
0.61% (14 Jan 2022)
End of year
0.32% (30 Dec 2022)
Change
-0.29 pp
High
0.73% (14 Oct 2022)
Low
0.32% (30 Dec 2022)
Average
0.49%
Highest days to cover
3.93 (15 Sep 2022)
SEC filings marked
8

Every report in 2022

Perspective Therapeutics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20220.61%1.73
31 Jan 20220.65%1.72
15 Feb 20220.60%1.60results (8-K), 10-Q filed
28 Feb 20220.50%2.24
15 Mar 20220.56%1.34
31 Mar 20220.61%1.95
14 Apr 20220.53%3.60
29 Apr 20220.55%2.97
13 May 20220.54%1.89results (8-K), 10-Q filed
31 May 20220.51%3.71
15 Jun 20220.51%2.00
30 Jun 20220.47%2.65
15 Jul 20220.47%3.45
29 Jul 20220.44%3.59
15 Aug 20220.46%2.33
31 Aug 20220.35%2.04
15 Sep 20220.37%3.93
30 Sep 20220.39%1.3210-K filed, results (8-K)
14 Oct 20220.73%1.78
31 Oct 20220.49%3.83
15 Nov 20220.35%2.10results (8-K), 10-Q filed
30 Nov 20220.37%1.63
15 Dec 20220.35%1.80
30 Dec 20220.32%1.34

See also: Perspective Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.